scPharmaceuticals (NASDAQ:SCPH – Get Free Report) and Purple Biotech (NASDAQ:PPBT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.
Volatility & Risk
scPharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Insider and Institutional Ownership
89.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 5.5% of scPharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| scPharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Purple Biotech | 0 | 0 | 1 | 0 | 3.00 |
scPharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 449.02%. Purple Biotech has a consensus price target of $33.00, indicating a potential upside of 1,275.00%. Given Purple Biotech’s higher probable upside, analysts plainly believe Purple Biotech is more favorable than scPharmaceuticals.
Valuation & Earnings
This table compares scPharmaceuticals and Purple Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| scPharmaceuticals | $36.33 million | 3.53 | -$54.81 million | ($1.90) | -1.34 |
| Purple Biotech | N/A | N/A | -$19.88 million | ($5.25) | -0.46 |
Purple Biotech has lower revenue, but higher earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares scPharmaceuticals and Purple Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| scPharmaceuticals | -264.60% | -244.93% | -68.56% |
| Purple Biotech | N/A | -55.86% | -44.67% |
Summary
Purple Biotech beats scPharmaceuticals on 7 of the 12 factors compared between the two stocks.
About scPharmaceuticals
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
